Guggenheim lowered the firm’s price target on BillionToOne (BLLN) to $100 from $120 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies in its diagnostics and life science tools coverage to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLLN: